This antibody has recently been successfully employed in the PG-APS model in which mAb C11C1 inhibited inflammatory changes in joints, systemic inflammation, and activation of the kallikrein–kinin system [20]. Here, KLK4 is linked to autoimmune polyendocrinopathy.